Fertility and Sterility, 106(7), e251-e256
What you will likely notice more during weeks 1-2 are side effects
Food and Drug Administration (FDA) has signaled a significant regulatory shift for 2026 by announcing increased enforcement against non-FDA-approved compounded GLP-1 products and potentially misleading promotional activities
Therefore, debate is still ongoing, although long-lasting active analogues of GLP-1 and inhibitors of DPP4 have already been developed as drugs
We found significantly increased prevalence of clinically relevant (symptomatic complicated and non-complicated) cholelithiasis among users of GLP-1RAs, in particular, liraglutide and semaglutide
Anesthetics, analgesics, and sedatives